California has plenty of anti-COVID drugs, but doctors aren't prescribing them

The drugs such as Paxlovid and molnupiravir are free and widely available, but officials say some doctors are not prescribing them as much as they should.

There are two antiviral pills available for eligible patients who have recently tested positive for the coronavirus. And they’re free.

Those who test positive for the coronavirus should promptly contact a healthcare provider because treatments need to begin within five to seven days following the onset of symptoms, according to the California Department of Public Health. COVID-19 treatment is recommended for anyone 12 and older with symptoms or has a positive test result and might be at higher risk for worse illness, state officials say.The Biden administration is making free coronavirus tests available to U.S. households again as part of a contingency plan for a possible COVID surge.

Unvaccinated people are also eligible for treatment. The medicine provides the biggest benefit to those individuals, officials say, but also helps vaccinated people and those who have survived an earlier COVID-19 illness.

Vi har oppsummert denne nyheten slik at du kan lese den raskt. Er du interessert i nyhetene kan du lese hele teksten her. Les mer:

latimes /  🏆 11. in US

Norge Siste Nytt, Norge Overskrifter

Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.

Rapid Heartbeat Condition 5 Times More Likely With COVID Than With COVID VaccineNew research has revealed a link between a lesser known heart syndrome and COVID infection, with a much smaller link seen between the condition and COVID vaccination.
Les mer »

China Meheco to distribute Pfizer's COVID treatment in ChinaChina Meheco Group Co Ltd said on Wednesday it signed an agreement with Pfizer Inc to import and distribute the U.S. drugmaker's oral COVID-19 treatment Paxlovid in mainland China, as the country braces for a surge in COVID patients after scaling back its 'zero COVID' policy.
Les mer »

U.S. to pay Pfizer nearly $2 bln for more Paxlovid courses in 2023The U.S. government agreed to pay Pfizer Inc nearly $2 billion for an additional 3.7 million courses of its COVID-19 antiviral treatment Paxlovid, the company said on Tuesday.
Les mer »